The Economics of High Dose Statin Therapy

It is well established that moderate statin therapy is clinically beneficial and economically attractive. And a few large trials have suggested that intensive, high dose therapy can result in further prevention of major cardiac events. But do these extra benefits justify the additional expense of the higher doses? That’s the question investigators from the Treating to New Targets (TNT) trial—a multicenter, double-blind, randomized, controlled trial that compared high and low dose atorvastatin therapy—set out to answer through a prospective, economic substudy.